BioBridgeXAll companies

Prolifagen, Inc.

Biotechnology company · Doylestown, Pennsylvania, United States

Prolifagen, Inc. is a biotechnology company headquartered in Doylestown, Pennsylvania, United States. Its earliest recorded incorporation is in 2025. It has received 1 US government small-business research award (SBIR/STTR) from health agencies, $273,069 in total, most recently in 2019. It has reported private securities offerings to the US SEC, most recently $3 million sold in a notice filed in 2025.

Profile compiled from public records. Is this your company? Request a correction or update

Prolifagen at a glance

Typebiotechnology company
HeadquartersDoylestown, Pennsylvania, United States
Earliest incorporation on record2025
Employees (self-reported, 2019)1
SEC CIK2086999

What does Prolifagen do?

US government research funding

1 SBIR/STTR small-business research award from US health agencies, $273,069 in total (2019). NIH funding came from the National Heart, Lung, and Blood Institute.

Private fundraising reported to the SEC

1 Form D notice; the most recent reported $3 million sold (2025).

Frequently asked questions about Prolifagen

Where is Prolifagen headquartered?

Prolifagen, Inc. is headquartered in Doylestown, Pennsylvania, United States.

What does Prolifagen do?

Prolifagen, Inc. is a biotechnology company.

When was Prolifagen founded?

The earliest incorporation on record for Prolifagen, Inc. is in 2025, according to public company registers.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Last updated 2026-09-25. Data licences